Overview

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Status:
Completed
Trial end date:
2017-03-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in participants with Familial Chylomicronemia Syndrome
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Akcea Therapeutics